Turkish Version of the Neurogenic Bladder Symptom Score Short Form

NCT07507331 | Completed

• 1 other identifier: 12024861-53
• Study Type: observational
• Target: 120
• Locations: 1 country
• Sites: 1

Brief Summary

This observational study aims to evaluate the cross-cultural adaptation and psychometric properties of the Turkish version of the Neurogenic Bladder Symptom Score Short Form (NBSS-SF) in adults with spinal cord injury or multiple sclerosis who have neurogenic lower urinary tract dysfunction. Neurogenic bladder symptoms, such as urinary incontinence, urgency, and difficulties with urine storage or emptying, may negatively affect daily functioning and quality of life. In this study, the validity and reliability of the Turkish NBSS-SF will be examined, and convergent validity will be assessed through its relationship with the King's Health Questionnaire (KHQ) and the Short Form-12 (SF-12). In eligible participants, the scale will be administered again after 7 to 14 days. The aim of the study is to provide a valid and reliable Turkish patient-reported outcome measure for use in clinical practice and research.

Conditions

Spinal Cord Injury; Multiple Sclerosis; Lower Urinary Track Symptoms; Neurogenic Bladder Disorder

Keywords

Neurogenic Bladder; Neurogenic Bladder Symptom Score- Short Form Validation; Spinal Cord Injury; Multiple Sclerosis

Outcome Measures

Primary Outcomes (1)

• Neurogenic Bladder Symptom Score Short Form (NBSS-SF) total score

  The Neurogenic Bladder Symptom Score Short Form (NBSS-SF) is a 10-item patient-reported outcome measure. It will be evaluated in adults with spinal cord injury or multiple sclerosis who have neurogenic lower urinary tract dysfunction. The NBSS-SF total symptom score ranges from 0 to 28, with lower scores indicating better symptom status and higher scores indicating worse symptom burden. Domain scores for incontinence, storage and voiding, and consequences will also be assessed. Psychometric evaluation will include internal consistency, test-retest reliability, and convergent validity.

  3 months

Other Outcomes (2)

• King's Health Questionnaire (KHQ) domain scores

  3 months

• 12-Item Short Form Health Survey (SF-12) mental and physical health subscale scores

  3 months

Study Arms (1)

Patients diagnosed with Spinal Cord Injury (SCI) or Multiple Sclerosis (MS) and neurogenic lower uri

Adults with spinal cord injury (SCI) or multiple sclerosis (MS) who have neurogenic lower urinary tract dysfunction will be included. Participants will complete the Turkish version of the Neurogenic Bladder Symptom Score Short Form (NBSS-SF), the King's Health Questionnaire (KHQ), and the Short Form-12 (SF-12). In clinically stable eligible participants, the Turkish NBSS-SF will be re-administered after 7 to 14 days to assess test-retest reliability.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study will be conducted on patients aged ≥18 years with neurogenic LUTS diagnosed with MS or SCI.

You may qualify if:

• Being ≥18 years old
• Having a diagnosis of Spinal Cord Injury (SCI) or Multiple Sclerosis (MS) and neurogenic lower urinary tract dysfunction
• Being able to read and understand Turkish and have the cognitive ability to independently complete questionnaires
• Can be included with any bladder management method (spontaneous voiding, CIC, permanent catheter, condom catheter, reconstruction/diversion etc.)
• Volunteering and signing informed consent

You may not qualify if:

• Having an active urinary tract infection (UTI)
• Having undergone urological surgery in the last month
• Reporting changes in bladder/urinary function between the first and second applications (surgery, UTI, change in bladder medication)
• Having a significant recent change in general health status
• Having a spinal cord injury (SCI) in the spinal shock phase
• Having experienced a relapse of Multiple Sclerosis (MS) within the last 3 months.

Sponsors & Collaborators

• Gaziantep Islam Science and Technology University: lead
• Ufuk University: collaborator

Study Sites (1)

Hacettepe University Hospital, Neurology Outpatient Clinic and Viransehir State Hospital, Urology Outpatient Clinic

Ankara, Çankaya, 06100, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Urinary Bladder, Neurogenic; Spinal Cord Injuries; Multiple Sclerosis

Condition Hierarchy (Ancestors)

Neurologic Manifestations; Nervous System Diseases; Urinary Bladder Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Spinal Cord Diseases; Central Nervous System Diseases; Trauma, Nervous System; Wounds and Injuries; Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Demyelinating Diseases; Autoimmune Diseases; Immune System Diseases

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor

Study Record Dates

• First Submitted: March 27, 2026
• First Posted: April 2, 2026
• Study Start: March 27, 2026
• Primary Completion: July 22, 2026
• Study Completion: July 22, 2026
• Last Updated: July 23, 2026

Record last verified: 2026-07

Locations

TU (1)